Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

Table 3 Comparison of median overall survival between the upfront surgery group and the neoadjuvant therapy plus surgery group

Ref.	Country	NCT number/Name	Variable	Upfront surgery	NAT plus surgery	P value
Golcher et al[7]	Germany	NCT00335543	mOS; mo	14.4	17.4	0.96
Versteijne et al[8]	Netherlands	PREOPANC	mOS; mo	14.6	15.6	0.83
Casadei et al[9]	Italy	-	mOS; mo	19.5	22.4	0.97
Reni et al[10]	Italy	PACT-15	mOS; mo	20.4,26.4	38.2	NM
Satoi et al[11]	Japan	Prep-02/JSAP-05	mOS; mo	26.6	36.7	0.015

NAT: Neoadjuvant therapy; mOS: Median overall survival; NM: Not mentioned.